Name | (1R,10S)-10-hydroxy-1,6-dimethyl-10-(2-oxopropyl)-1,2-dihydronaphtho[1,2-g][1]benzofuran-11-one |
---|---|
Synonyms | Danshenol A |
Description | Danshenol A, an abietane-type diterpenoid, is an aldose reductase (AR) inhibitor with an IC50 of 0.1 μM. Danshenol A can protect endothelial cells from oxidative stress by directly scavenging ROS. Danshenol A has anti-inflammatory and antitumor properties. Danshenol A can be used for atherosclerosis research[1][2][3][4]. |
---|---|
Related Catalog | |
Target |
IC50: 0.1 μM (Aldose reductase)[3] |
In Vitro | Danshenol A (10 nM; pretreatment for 1 h) 单独处理显示对 ICAM-1 在 mRNA 和蛋白质水平的表达没有影响。Danshenol A 显着逆转 TNF-α 诱导的 ICAM-1 表达和随后的单核细胞粘附,以及升高的活性氧 (ROS) 生成和 NOX4 表达[1]. Danshenol A 通过 NOX4 依赖性 IKKβ/NF-κB 通路抑制 TNF-α 诱导的 ICAM-1 表达和随后的单核细胞与内皮细胞的粘附[1]。 Danshenol A (1, 3, and 10 μM; pretreated for 35 min) 恢复血管紧张素 II 诱导的心肌细胞凋亡。此外,Danshenol A 抑制心肌细胞线粒体氧化还原信号通路[2]。 Danshenol A 抑制 K562 (IC50 = 0.53 μg/mL)、T-24 (IC50 = 7.94 μg/mL)、QGY (IC50 = 4.65 μg/mL) 和 Me180 (IC50 = 6.89 μg/mL) 细胞系的活性[4]。 Western Blot Analysis[1] Cell Line: HUVEC cells Concentration: 10 nM Incubation Time: Pretreatment for 1 h Result: Showed no effect on the ICAM-1 expression at both mRNA and protein levels. |
In Vivo | Danshenol A (0.3-3mg/kg;口服;每天一次;持续 12 周) 改善 SHR 大鼠的血压、心脏损伤和心肌胶原体积,并改善心功能。Danshenol A 修复线粒体结构/功能,减轻心肌氧化应激[2]。 Animal Model: Forty male spontaneously hypertensive rats (SHR) and eight male Wistar-Kyoto (WKY) rats at the age of 16 weeks[2] Dosage: 0.3 mg/kg, 1 mg/kg, 3 mg/kg Administration: Orally administration; daily; for 12 weeks Result: Ameliorated blood pressure, cardiac injury, and myocardial collagen volume and improved cardiac function. |
References |
Density | 1.31±0.1 g/cm3 |
---|---|
Boiling Point | 571.5ºC at 760 mmHg |
Molecular Formula | C21H20O4 |
Molecular Weight | 336.38100 |
Flash Point | 206.6ºC |
Exact Mass | 336.13600 |
PSA | 63.60000 |
LogP | 3.27500 |
Vapour Pressure | 6.74E-14mmHg at 25°C |
Index of Refraction | 1.653 |